AQR Capital Management LLC Has $590,000 Stake in Revvity, Inc. (NYSE:RVTY)

AQR Capital Management LLC lessened its stake in shares of Revvity, Inc. (NYSE:RVTY) by 2.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,630 shares of the company’s stock after selling 118 shares during the quarter. AQR Capital Management LLC’s holdings in Revvity were worth $590,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Rothschild Investment LLC purchased a new stake in shares of Revvity during the 2nd quarter worth approximately $25,000. EverSource Wealth Advisors LLC increased its stake in shares of Revvity by 74.2% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 392 shares of the company’s stock worth $41,000 after purchasing an additional 167 shares during the last quarter. Fairfield Financial Advisors LTD purchased a new stake in shares of Revvity during the 2nd quarter worth approximately $43,000. Family Firm Inc. purchased a new stake in shares of Revvity during the 2nd quarter worth approximately $43,000. Finally, EntryPoint Capital LLC purchased a new stake in shares of Revvity during the 1st quarter worth approximately $48,000. Institutional investors own 86.65% of the company’s stock.

Insider Buying and Selling at Revvity

In other news, insider Tajinder S. Vohra sold 2,153 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $122.09, for a total transaction of $262,859.77. Following the completion of the transaction, the insider now directly owns 23,960 shares of the company’s stock, valued at approximately $2,925,276.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, insider Tajinder S. Vohra sold 2,153 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $122.09, for a total value of $262,859.77. Following the completion of the transaction, the insider now directly owns 23,960 shares of the company’s stock, valued at $2,925,276.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Joel S. Goldberg sold 3,500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $117.86, for a total transaction of $412,510.00. Following the transaction, the insider now directly owns 33,400 shares of the company’s stock, valued at $3,936,524. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 7,807 shares of company stock worth $937,576 over the last three months. Company insiders own 0.60% of the company’s stock.

Revvity Stock Up 1.2 %

Shares of NYSE:RVTY opened at $122.91 on Tuesday. The firm has a fifty day moving average of $121.42 and a 200 day moving average of $112.63. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.98 and a current ratio of 2.27. Revvity, Inc. has a 52-week low of $79.50 and a 52-week high of $128.15. The firm has a market capitalization of $15.17 billion, a PE ratio of 101.58, a price-to-earnings-growth ratio of 3.35 and a beta of 1.05.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Monday, July 29th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.10. Revvity had a net margin of 6.26% and a return on equity of 7.34%. The business had revenue of $691.70 million during the quarter, compared to analyst estimates of $690.33 million. During the same period in the prior year, the business posted $1.21 earnings per share. The company’s revenue was down 2.5% on a year-over-year basis. As a group, research analysts anticipate that Revvity, Inc. will post 4.75 EPS for the current fiscal year.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 8th. Shareholders of record on Friday, October 18th will be given a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, October 18th. This represents a $0.28 annualized dividend and a yield of 0.23%. Revvity’s payout ratio is 23.14%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on RVTY. Barclays raised their price target on shares of Revvity from $115.00 to $125.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 30th. TD Cowen lifted their price objective on shares of Revvity from $130.00 to $141.00 and gave the company a “buy” rating in a research note on Tuesday, July 30th. Bank of America lifted their price objective on shares of Revvity from $118.00 to $127.00 and gave the company a “neutral” rating in a research note on Tuesday, July 30th. Leerink Partners began coverage on shares of Revvity in a research note on Monday, July 8th. They issued an “outperform” rating and a $125.00 price objective for the company. Finally, Jefferies Financial Group lifted their price objective on shares of Revvity from $115.00 to $125.00 and gave the company a “hold” rating in a research note on Monday, July 29th. Eight analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $125.53.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.